Baird Medical Expands U.S. Footprint with NASOIE 2026 Engagement
Event summary
- Baird Medical (BDMD) participated in the 2026 NASOIE Annual Meeting in Miami, Florida, to discuss its proprietary Microwave Ablation (MWA) technology with top-tier clinicians.
- The company gathered clinical feedback to inform its commercial roadmap for expanding patient access to minimally invasive therapies.
- Baird Medical's solutions are used in over 30 prestigious hospitals and clinics across the United States.
- The company is also the market leader in China in thyroid microwave ablation devices and consumables.
The big picture
Baird Medical's participation in NASOIE 2026 underscores its strategic focus on physician education and expanding access to minimally invasive therapies. The company's engagement with top-tier clinicians and its presence in over 30 U.S. hospitals highlight its growing influence in the interventional endocrinology space. As the market leader in China for thyroid microwave ablation devices, Baird Medical is positioning itself for further international expansion.
What we're watching
- Clinical Adoption
- How the feedback from NASOIE 2026 will shape Baird Medical's commercial strategy and product development.
- Market Expansion
- Whether Baird Medical can sustain its growth trajectory in the U.S. while maintaining its leadership position in China.
- Regulatory Dynamics
- The pace at which regulatory developments could impact Baird Medical's expansion plans and product approvals.
Related topics